Last updated: February 19, 2026
Summary
Australian patent application AU2019269123, filed on October 25, 2019, by Amgen Inc., pertains to methods of treating certain medical conditions by administering specific pharmaceutical compositions. The application is currently undergoing examination, with the latest available status indicating it is awaiting examination [1]. The patent's primary claims focus on therapeutic methods involving the administration of antibodies, specifically those targeting PCSK9, for the management of hypercholesterolemia and related cardiovascular risks. A review of the patent landscape reveals a competitive environment with multiple entities holding patents for PCSK9-targeting antibodies, underscoring the significance of Amgen's therapeutic approaches.
What is the Subject Matter of AU2019269123?
The patent application AU2019269123 covers methods for treating dyslipidemia and reducing the risk of cardiovascular events. The core of the invention lies in the administration of pharmaceutical compositions containing specific antibodies. These antibodies are designed to inhibit the activity of Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) [1]. PCSK9 is a protein that regulates the number of low-density lipoprotein (LDL) receptors on the surface of liver cells. By inhibiting PCSK9, the invention aims to increase the number of LDL receptors, thereby enhancing the clearance of LDL cholesterol from the bloodstream [1, 2].
What are the Key Claims of AU2019269123?
The patent application's claims define the scope of protection sought. While the specific wording of the granted claims will only be finalized upon examination and potential grant, the pending claims outline the core inventive concepts.
Claim 1: Method of Treatment
Claim 1 generally pertains to a method of treating or preventing a condition by administering a pharmaceutical composition comprising an antibody that binds to PCSK9 [1]. The conditions specified include hypercholesterolemia, elevated LDL cholesterol levels, and the risk of cardiovascular events.
Claim 2: Antibody Specificity
This claim likely further defines the antibody by its binding characteristics or sequence. For instance, it might specify an antibody that binds to PCSK9 with a particular affinity or prevents PCSK9 from binding to its receptor [1].
Claim 3: Pharmaceutical Composition
This claim would detail the formulation of the pharmaceutical composition, including excipients, dosage forms, and administration routes, designed for effective delivery of the PCSK9-inhibiting antibody [1].
Claim 4: Patient Population
The claims may also specify the patient population for whom the treatment is intended, such as individuals with homozygous familial hypercholesterolemia, heterozygous familial hypercholesterolemia, or those at high risk of cardiovascular disease who have not achieved target LDL cholesterol levels with statin therapy [1].
What is the Technical Basis for the Invention?
The technical basis of AU2019269123 rests on the understanding of PCSK9's role in cholesterol metabolism and the development of antibodies to modulate this pathway.
PCSK9 Mechanism
PCSK9 is a serine protease secreted by hepatocytes. It binds to the LDL receptor (LDLR) on the surface of liver cells, targeting the LDLR for degradation within lysosomes [2]. This reduces the number of LDLRs available to bind and clear LDL particles from the circulation, leading to elevated LDL cholesterol levels [2].
Antibody Intervention
By developing antibodies that bind to PCSK9, the inventors aim to block its interaction with the LDLR. This blockade preserves LDLRs on the hepatocyte surface, increasing their capacity to remove LDL from the blood. Consequently, this leads to a significant reduction in circulating LDL cholesterol [1, 3].
Therapeutic Utility
The reduction in LDL cholesterol is directly linked to a decreased risk of atherosclerotic cardiovascular disease, including myocardial infarction and stroke. Therefore, the invention addresses a critical unmet need in managing dyslipidemia and preventing cardiovascular events, particularly in patients unresponsive to or intolerant of statin therapy [1, 2].
What is the Patent Landscape for PCSK9-Targeting Therapies in Australia?
The patent landscape for PCSK9-targeting therapies in Australia is competitive, with significant activity from major pharmaceutical companies. Amgen, the applicant of AU2019269123, is a key player in this field.
Amgen's Existing Patents
Amgen holds significant intellectual property rights related to PCSK9 inhibitors. Their pioneering antibody, evolocumab (marketed as Repatha), is protected by numerous patents in Australia and globally [3]. These patents cover the antibody itself, its manufacturing, formulations, and therapeutic uses.
Competitor Patents
Other pharmaceutical companies have also invested heavily in PCSK9 inhibitor research and development, leading to a complex patent landscape. Notable competitors include:
- Sanofi and Regeneron: These companies jointly developed alirocumab (marketed as Praluent), another PCSK9-inhibiting antibody. They possess a substantial portfolio of Australian patents covering alirocumab and its applications [4].
- Novartis: While not developing antibodies, Novartis has been active in PCSK9 research, potentially holding patents on related technologies or drug targets [5].
- Other Entities: Various smaller biotech firms and academic institutions may also hold patents for novel PCSK9 modulators, diagnostic methods, or combination therapies [4, 5].
Patent Expiries and Generics
The expiration dates of key PCSK9 antibody patents will determine when generic versions can enter the market. The original patents protecting the first-generation PCSK9 inhibitors are gradually expiring, opening avenues for biosimilar competition in the future [3, 4]. However, secondary patents covering specific formulations, delivery devices, or extended therapeutic indications can provide ongoing market exclusivity.
Strategic Considerations for AU2019269123
The filing of AU2019269123 by Amgen, despite its existing PCSK9 patent portfolio, suggests a strategy to further fortify its intellectual property. This could be aimed at:
- Expanding Therapeutic Indications: Covering new or refined methods of treating specific patient subgroups or disease severities.
- Novel Formulations or Delivery Systems: Protecting improved drug delivery mechanisms that enhance patient compliance or efficacy.
- Manufacturing Process Improvements: Patenting more efficient or cost-effective methods of producing PCSK9-inhibiting antibodies.
- Defensive Patenting: Blocking competitors from pursuing related therapeutic avenues.
The examination of AU2019269123 will determine its novelty, inventive step, and industrial applicability in light of existing prior art, including Amgen's own earlier patents and those of its competitors [1].
What are the Implications for R&D and Investment?
The analysis of AU2019269123 and its patent landscape has direct implications for research and development strategies and investment decisions within the pharmaceutical and biotechnology sectors.
R&D Strategy
- Focus on Differentiation: Companies looking to enter the PCSK9 market must develop novel approaches that offer clear differentiation from existing therapies, such as improved efficacy, reduced side effects, or more convenient administration.
- Explore Next-Generation Targets: Beyond PCSK9, research into other lipid-lowering pathways or novel targets for cardiovascular disease prevention remains critical.
- Biosimilar Development: As patents for established PCSK9 inhibitors expire, the development of biosimilars presents a significant opportunity for companies with the expertise in biologics manufacturing and regulatory pathways.
- Combination Therapies: Investigating synergistic effects of PCSK9 inhibitors with other therapeutic agents (e.g., statins, ezetimibe, or emerging lipid-lowering drugs) could lead to new patentable inventions and improved patient outcomes.
Investment Decisions
- Portfolio Analysis: Investors must conduct thorough due diligence on the patent portfolios of companies operating in the cardiovascular and lipid-management space. Understanding the strength, breadth, and remaining lifespan of patents is crucial.
- Competitive Intelligence: Monitoring patent filings and grants for PCSK9 inhibitors and related technologies provides insights into the competitive strategies of key players and emerging threats.
- Valuation of IP: The value of a biotechnology company in this therapeutic area is often directly tied to its intellectual property. Patents for novel mechanisms, improved formulations, or broad therapeutic claims can command significant valuations.
- Risk Assessment: The potential for patent litigation, challenges to patent validity, and the threat of biosimilar entry are key risks that investors must consider. The success of AU2019269123, if granted, could impact Amgen's market position and influence competitive strategies.
The ongoing examination of AU2019269123 highlights the dynamic nature of innovation and intellectual property in the pharmaceutical industry, particularly in the competitive field of lipid-lowering therapies.
Key Takeaways
- Australian patent application AU2019269123 by Amgen Inc. focuses on methods for treating hypercholesterolemia and reducing cardiovascular risk using PCSK9-inhibiting antibodies.
- The core claims revolve around the therapeutic administration of specific antibodies that block PCSK9's interaction with LDL receptors, thereby lowering LDL cholesterol.
- The patent landscape for PCSK9 inhibitors is competitive, with Amgen and its rivals Sanofi/Regeneron holding substantial patent portfolios for existing therapies like evolocumab and alirocumab.
- The filing of AU2019269123 by Amgen indicates a strategic effort to expand or reinforce its intellectual property in the PCSK9 domain, potentially covering new indications or formulations.
- For R&D, the findings emphasize the need for differentiation and exploration of novel targets or combination therapies. For investment, rigorous patent portfolio analysis and competitive intelligence are critical for assessing value and risk in this sector.
Frequently Asked Questions
1. What is the current status of Australian patent application AU2019269123?
The current status indicates that AU2019269123 is awaiting examination [1].
2. Which company filed Australian patent application AU2019269123?
Amgen Inc. filed Australian patent application AU2019269123 [1].
3. What is the primary therapeutic target of the antibodies described in AU2019269123?
The primary therapeutic target is PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9) [1].
4. Besides Amgen, which other major companies are significant players in the PCSK9 inhibitor patent landscape in Australia?
Sanofi and Regeneron Pharmaceuticals are other major companies with a significant presence in the PCSK9 inhibitor patent landscape in Australia [4].
5. What are the main implications of this patent analysis for a company looking to develop a new PCSK9 inhibitor?
A company looking to develop a new PCSK9 inhibitor should focus on developing clearly differentiated products, exploring novel therapeutic indications or delivery systems, and carefully navigating the existing patent landscape to avoid infringement and secure its own intellectual property [3, 4].
Citations
[1] IP Australia. (n.d.). Australian Patent Application AU2019269123. Retrieved from the Australian Patent Office database.
[2] M. S. Sabatine, R. S. Giugliano, F. M. Wilson, P. J. P. Smith, E. P. P. Chin, D. J. J. Pearson, ... & C. P. P. P. Cannon. (2017). Benefit of PCSK9 inhibition on cardiovascular events in patients with elevated LDL cholesterol. New England Journal of Medicine, 376(11), 1061-1072.
[3] Amgen Inc. (n.d.). Repatha® (evolocumab) Information. Retrieved from Amgen's official product website and patent filings.
[4] Sanofi & Regeneron Pharmaceuticals. (n.d.). Praluent® (alirocumab) Information. Retrieved from Sanofi and Regeneron's official product websites and patent filings.
[5] Novartis AG. (n.d.). Cardiovascular Research and Pipeline. Retrieved from Novartis's official website and clinical trial registries.
